Garry Airaudeau PhD

Garry Pairaudeau is currently Head of Hit Discovery at AstraZeneca; the group comprising HTS, Comp Chem, Virtual screening, and DEL is responsible for generating high-quality starting points for AstraZeneca. In addition, the group works extensively with academic centers of excellence through open innovation and strategic collaborations with groups such as MRC, CRUK, Life Arc, and many others to help support academic drug discovery.

Garry also chairs the Global Chemistry Leadership team in AstraZeneca responsible for chemistry strategy and has been particularly active in building Automation and Machine learning capabilities. He joined AstraZeneca in 1994 as a medicinal chemist and was part of the chemistry team that discovered Brilinta. Prior to taking up his current position in 2012, he was Director of Chemistry for the cardiovascular group at Alderley Park.